Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H596
UPID:
DUS21_HUMAN
Alternative names:
Low molecular weight dual specificity phosphatase 21
Alternative UPACC:
Q9H596; Q0VDA6; Q6IAJ6; Q6YDQ8
Background:
Dual specificity protein phosphatase 21, also known as Low molecular weight dual specificity phosphatase 21, plays a crucial role in cellular processes by dephosphorylating MAPK peptides. It exhibits a preference for phosphotyrosine and diphosphorylated forms, highlighting its specificity and importance in signal transduction pathways.
Therapeutic significance:
Understanding the role of Dual specificity protein phosphatase 21 could open doors to potential therapeutic strategies. Its precise function in dephosphorylation positions it as a key target for drug discovery, aiming to modulate cellular signaling for therapeutic benefits.